E like me ka ʻike o ka hōʻike, ka honua mākeke kiʻi biomarker multiplex ua manaʻo ʻia e ʻike i ka ulu nui ʻana i ka wā wānana, ma muli o ka ulu nui ʻana o ka noi no nā ʻenehana immunofluorescence holomua e kōkua i ka maʻi ʻoi aku ka maikaʻi a me ka hoʻokele ʻana i nā maʻi maʻi ma kahi pae cellular.
Ua kūʻai ʻia ka mākeke kiʻi biomarker multiplex honua i $ 422.1 Mn i 2021, a ke manaʻo ʻia e hoʻonui i kahi CAGR o 11.9% ma luna o ka wānana o 2022-2029.
ʻO nā mea nui o ka Multiplex Biomarker Imaging Market Study
- Aia ke koi mau no ka immunofluorescence slide scanners, no ka mea, hāʻawi kēia mau mea i ke ʻano kiʻi kiʻekiʻe kiʻekiʻe, hilinaʻi, a me ka wikiwiki no ke kiʻi paheʻe holoʻokoʻa.
- Manaʻo ʻia ʻo ʻAmelika ʻĀkau he mākeke maikaʻi no ka multix biomarker imaging, no ka hoʻomohala ʻana i nā ʻōnaehana olakino, nā kulekele aupuni maikaʻi, a me nā haʻawina kālā no ka noiʻi ʻana e ke aupuni.
- Hoʻohana nui ʻia ka Immunostaining i ka ʻike ʻana i nā cell abnormal, e like me nā cell cancerous, a kōkua pū i ka hoʻomaopopo ʻana i ka hoʻohele a me ka localization o nā biomarkers a me nā protein i hōʻike ʻokoʻa ʻia i nā ʻāpana like ʻole o kahi kiko olaola.
- ʻO ka kūleʻa pāʻoihana o ka mākeke kiʻi biomarkers multiplex e hilinaʻi nui ʻia i nā noiʻi noiʻi maʻi kanesa, hiki ke lawelawe i nā kumu he nui e like me ka ʻike ʻana i nā cell cancerous, ka hele ʻana o nā necrotic agents, a me ka loiloi ʻana i nā mea kūlohelohe a me ka hana ʻana i ka anatomy cellular.
ʻO nā mea pāʻani papa 1 e paʻa ma mua o 80% o ka loaʻa kālā
ʻO PerkinElmer, Bio-Rad, a me Thermo Fisher Scientific kekahi o nā mea pāʻani mākeke i ka mākeke kiʻi biomarker multiplex. Ke hoʻomau nei kēia mau mea hana i ka ʻāina o ka mākeke kiʻi biomarker multiplex ma muli o ko lākou manaʻo nui i ka hana hou ʻana o ka huahana, alakaʻi mākeke i ka hoʻolauna huahana, a me ka pūnaewele hoʻolaha ikaika me nā laboratories unuhi a me nā keʻena kula e hoʻonui i nā kūʻai.
Noi i TOC piha o keia hoike @ https://www.futuremarketinsights.com/toc/rep-gb-3526
Makemake ʻoe i nā ʻike hou aʻe?
Ua aʻo ʻo Future Market Insights i ka ulu ʻana o ka mākeke kiʻi biomarker multiplex mai 2014–2021, a hōʻike i nā kuhi koi no 2022–2029, ma ke kumu o nā ʻano mea (mea kani, lako polokalamu, a me nā lawelawe), ʻenehana kiʻi (IHC assays, FISH assays. , TMA assays), noi (noiʻi a me ka clinical diagnostics), a me ka mea hoʻohana hope (unuhi laboratories, biopharmaceutical company, and academic institute) ma ʻehiku mau ʻāina koʻikoʻi.
Multiplex Biomarker Imaging Market e ka ʻāpana
Ma ke ʻano ʻano mea:
- Nā mea kani
- Pūnaehana Kiʻi Pathology Quantitative
- Immunofluorescence
- Pūnaehana Kiʻi Multispectral
- Pūnaehana Kiʻi Toponome
- lako polokalamu
- Services
- Nā lawelawe hoʻokomo a hoʻohui
- Nā lawelawe mālama
Ma ka ʻenehana kiʻi:
- ʻIkepili Immunohistochemistry (IHC).
- Hōʻike ʻo Fluorescent In Situ Hybridization (FISH).
- Tissue Microarray (TMA) Assay
Ma ke noi:
- Research
- Nā Hoʻopaʻa Ola
Na ka mea hoʻohana hope:
- Nā Laboratories unuhi
- Nā Hui Lapaʻau Biopharmaceutical
- Nā Hale Hoʻonaʻauao
Ma ka Hona:
- North America
- Lakina Amerika
- ʻO Ke Komohana Komohana
- HawaiianʻEulopa
- ʻĀkia Pākīpika ʻē aʻe i Iapana (APEJ)
- Iapana
- Waena Hikina a me ʻApika
Kūʻai i kēia manawa @ https://www.futuremarketinsights.com/checkout/3526